Sarah R. Hosford

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

T. Miller, Sarah R. Hosford, Sarah R Hosford, 2014, Pharmacogenomics and personalized medicine.

High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer

E. Demidenko, T. Miller, Nicole A. Traphagen, 2021, Oncogene.

Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer

E. Demidenko, A. Kettenbach, K. Shee, 2019, Molecular oncology.

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha–Positive, PIK3CA-Mutant Breast Cancer

A. Eastman, D. Bates, E. Demidenko, 2016, Clinical Cancer Research.

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer

G. Schwartz, Wei Yang, K. Shee, 2014, Breast Cancer Research and Treatment.

Autophagy promotes escape from phosphatidylinositol 3‐kinase inhibition in estrogen receptor‐positive breast cancer

E. Demidenko, Wei Yang, K. Shee, 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.